Evidence map›Paper›PMID 40818978›Full record

ArticleScientific reports2025

Exosome mediated delivery of Epigallocatechin 3 gallate as a novel approach to alleviate psoriasis symptoms through cytokine and apoptotic pathway modulation.

Mohamed S Kishta, Ahmed A Abd-Rabou, Garo K Sarkissian, Ahmed I Elwakil, Dana M Elsabry, Youssef M Zagzoug, Sohaila R Hussein, Ahmed N Abdallah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations.Clinical, cosmetic and investigational dermatology · 2026
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed S KishtaHormones department, Medical Research and clinical studies institute, National Research Centre, Dokki, Cairo, 12622, Egypt. kishtamsa@gmail.com.ORCID http://orcid.org/0000-0002-2314-8820
Ahmed A Abd-RabouHormones department, Medical Research and clinical studies institute, National Research Centre, Dokki, Cairo, 12622, Egypt.
Garo K SarkissianBiotechnology Faculty, October University for Modern Sciences and Arts (MSA), 6th of October City, Giza, 12451, Egypt.
Ahmed I ElwakilBiotechnology Faculty, October University for Modern Sciences and Arts (MSA), 6th of October City, Giza, 12451, Egypt.
Dana M ElsabryBiotechnology Faculty, October University for Modern Sciences and Arts (MSA), 6th of October City, Giza, 12451, Egypt.
Youssef M ZagzougBiotechnology Faculty, October University for Modern Sciences and Arts (MSA), 6th of October City, Giza, 12451, Egypt.
Sohaila R HusseinBiotechnology Faculty, October University for Modern Sciences and Arts (MSA), 6th of October City, Giza, 12451, Egypt.
Ahmed N AbdallahHormones department, Medical Research and clinical studies institute, National Research Centre, Dokki, Cairo, 12622, Egypt. an.noureldine@nrc.sci.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a chronic skin disorder with significant individual and societal impacts. Current therapies often lack efficacy, are costly, or cause side effects, necessitating new treatments. This study explores regenerative therapies-exosomes, mesenchymal stem cells (MSCs), epigallocatechin-3-gallate nanoparticles (EGN), and EGN-loaded exosomes (EGN-Exo)-in regulating psoriasis-related markers (IL-6, IL-4, Bcl-2, Bax, NF-κB, CDC25B). An imiquimod-induced psoriasis model in Wistar rats was used, with six groups: negative control, positive control, and treatments (MSCs, exosomes, EGN, EGN-Exo). After seven days, ELISA revealed EGN-Exo most effectively reduced pro-inflammatory IL-6 and pro-apoptotic Bax while increasing anti-inflammatory IL-4 and anti-apoptotic Bcl-2. EGN-Exo also significantly lowered NF-κB and CDC25B, demonstrating superior anti-inflammatory effects. Apoptosis profiling showed EGN-Exo reduced late apoptotic cells, highlighting cytoprotective abilities. EGN had a moderate effect, while MSCs and exosomes showed modest improvements. Histopathological and immunohistochemical analyses confirmed EGN-Exo's efficacy, notably reducing TGF-β expression. These findings suggest EGN-Exo combines EGCG's antioxidant and anti-inflammatory properties with exosomes' targeted delivery, offering a promising advanced therapy for psoriasis.

Indexed as

ApoptosisExosomesNanoparticlesNF-kappa BPsoriasisAnimalsCatechincdc25 PhosphatasesCytokinesDisease Models, AnimalMaleMesenchymal Stem CellsRatsRats, WistarSignal TransductionCatechincdc25 PhosphatasesCytokinesepigallocatechin gallateNF-kappa BBone marrow mesenchymal stem cellsEpigallocatechin-3-gallate-loaded exosomesEpigallocatechin-3-gallate nanoparticlesPsoriasisStem cell-derived exosomes

Identifiers

PMID40818978
PMCPMC12357947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.